Companies › SK Bioscience
3 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NBP608 (Mid Potency) Live attenuated varicella virus vaccine (Oka/SK strain) | – | Phase 3 | Varicella (Chickenpox) | Feb 2027 |
| GBP511 Broadly protective sarbecovirus vaccine | – | Phase 1 | Healthy Participants | Dec 2026 |
| GBP511 + CAS-1 Broadly protective sarbecovirus vaccine with adjuvant | – | Phase 1 | Healthy Participants | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07280858 | GBP511 | Phase 1 | Healthy Participants | Infectious disease | Dec 2026 |
| NCT07280858 | GBP511 + CAS-1 | Phase 1 | Healthy Participants | Infectious disease | Dec 2026 |
| NCT07415252 | NBP608 (Mid Potency) | Phase 3 | Varicella (Chickenpox) | Infectious disease | Feb 2027 |
| NCT07415252 | NBP608 (Mid Potency) | Phase 3 | Varicella (Chickenpox) | Infectious disease | Feb 2027 |
No annotated target.
–
Inventprise LimmaTech Biologics Sinovac Life Sciences Bharat Biotech International Immorna Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.